Reshape Lifesciences Q2 EPS $(0.06) Up From $(1.08) YoY, Sales $1.97M Miss $2.21M Estimate
Portfolio Pulse from saritha@benzinga.com
Reshape Lifesciences (NASDAQ:RSLS) reported Q2 EPS of $(0.06), a significant improvement from $(1.08) YoY, but missed sales estimates with $1.97M, down 12.82% YoY.
August 14, 2024 | 8:11 pm
News sentiment analysis
Sort by:
Ascending
NEUTRAL IMPACT
Reshape Lifesciences reported a significant improvement in EPS for Q2, but missed sales estimates and showed a YoY decline in revenue.
While the EPS improvement is a positive sign, the miss on sales estimates and the YoY decline in revenue could neutralize the positive sentiment, leading to a mixed short-term impact on the stock price.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100